EA199900914A1 - Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена - Google Patents

Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена

Info

Publication number
EA199900914A1
EA199900914A1 EA199900914A EA199900914A EA199900914A1 EA 199900914 A1 EA199900914 A1 EA 199900914A1 EA 199900914 A EA199900914 A EA 199900914A EA 199900914 A EA199900914 A EA 199900914A EA 199900914 A1 EA199900914 A1 EA 199900914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
prostate cancer
benign prostatic
prostatic hyperplasia
prophylaxis
Prior art date
Application number
EA199900914A
Other languages
English (en)
Inventor
Блэйк Ли Нюбоер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900914A1 publication Critical patent/EA199900914A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Данное изобретение предлагает способ лечения или профилактики доброкачественной гиперплазии простаты или рака простаты у пациента, нуждающегося в таком лечении, включающий в себя введение селективно модулирующего рецепторы эстрогена соединения формулы (I)где Rи Rнезависимо представляют собой гидрокси и алкокси, содержащий от одного до четырех атомов углерода, Rи Rнезависимо представляют собой метил или этил, или Rи R, взятые вместе с атомом азота, к которому они присоединены, образуют пирролидиновое, метилпирролидиновое, диметилпирролидиновое, пиперидиновое, морфолиновое или гексаметилениминовое кольцо.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900914A 1997-04-09 1998-04-07 Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена EA199900914A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
EA199900914A1 true EA199900914A1 (ru) 2000-04-24

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900914A EA199900914A1 (ru) 1997-04-09 1998-04-07 Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена

Country Status (16)

Country Link
EP (1) EP0975629A4 (ru)
JP (1) JP2001518900A (ru)
KR (1) KR20010006218A (ru)
CN (1) CN1259944A (ru)
AU (1) AU6966198A (ru)
BR (1) BR9808515A (ru)
CA (1) CA2286204A1 (ru)
EA (1) EA199900914A1 (ru)
HU (1) HUP0003589A3 (ru)
ID (1) ID24358A (ru)
IL (1) IL132277A0 (ru)
NO (1) NO994903L (ru)
PL (1) PL336205A1 (ru)
TR (1) TR199902701T2 (ru)
WO (1) WO1998045288A1 (ru)
ZA (1) ZA982819B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US20020198235A1 (en) * 2001-05-10 2002-12-26 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
WO2007135547A2 (en) * 2006-05-22 2007-11-29 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
MY150082A (en) 2007-10-16 2013-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US8877801B2 (en) 2013-02-19 2014-11-04 Novartis Ag Compounds and compositions as selective estrogen receptor degraders
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
PE44597A1 (es) * 1995-02-28 1997-10-13 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
CN1259944A (zh) 2000-07-12
WO1998045288A1 (en) 1998-10-15
NO994903L (no) 1999-12-09
ZA982819B (en) 1999-10-04
CA2286204A1 (en) 1998-10-15
EP0975629A4 (en) 2001-03-21
HUP0003589A3 (en) 2002-02-28
TR199902701T2 (xx) 2000-02-21
EP0975629A1 (en) 2000-02-02
ID24358A (id) 2000-07-13
NO994903D0 (no) 1999-10-08
HUP0003589A2 (hu) 2002-01-28
AU6966198A (en) 1998-10-30
PL336205A1 (en) 2000-06-05
JP2001518900A (ja) 2001-10-16
KR20010006218A (ko) 2001-01-26
IL132277A0 (en) 2001-03-19
BR9808515A (pt) 2001-06-19

Similar Documents

Publication Publication Date Title
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DK1019060T3 (da) Androgensynteseinhibitorer
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
DE69815313D1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
AP9901478A0 (en) Compounds for the treatment of ischemia.
DK0480950T3 (da) Kombinationsterapi til profylakse for og/eller behandling af godartet prostatahypertrofi
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
TR199901104T2 (xx) Farmas�tik bile�ikler.
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
ATE156839T1 (de) Neue delta-17 und delta-20 ungesätigte und gesatigte 17--g(b)-substituierte-4-aza-5-g(a)- androstan-3-on verbindungen als inhibitoren von 5-alpha-reductase
DE69814894T2 (de) Isochinolin derivate als urokinase inhibitoren
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
HUP0100781A2 (hu) A jóindulatú prosztata hiperplázia kezelésére alkalmas szubsztituált piridino aril piperazin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
AR014352A1 (es) Mezclas fungicidas y procedimiento para controlar hongos nocivos con dichas mezclas
EA199800058A1 (ru) Способ лечения доброкачественной гиперплазии предстательной железы, лекарственная форма для лечения доброкачественной гиперплазии, содержащая агонист мелатонина
ATE222263T1 (de) Prostata-spezifische antigen inhibitore
ATE339415T1 (de) Benzocarbazol und indenoindole derivate als östrogene agentien
IT1265237B1 (it) Derivati basici dell'indolo
ITMI920850A0 (it) Benzofurano-imidazoli per uso come inibitori di aromatisie 17,20-liasinella rpofilassi e trattamento del cancro della mammella e nell'iper- plasia prostatica benigna